AstraZeneca Warns UK on Innovation | FT Business
  • 5 years ago
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs

A decision by the UK’s National Health Service not to stock a new cancer drug being sold by AstraZeneca has seen the British pharmaceuticals company accuse the country of stymieing scientific innovation. The FT's Andrew Ward explains the predicament.

► FT Business: http://bit.ly/1KUK08s

► FT Markets: http://bit.ly/1J5HNd3

► NHS Struggles to Boost Productivity: http://bit.ly/1er08o1